It should be noted that the sluv has not been wheeled out by cynata for the best part of three years.
He is himself a major shareholder, so if nothing else any comments he makes on the company would need to be properly signalled to market.
I think long term holders who have followed cynata can ready a lot into this and the topics covered ...
It is, if you like, a scene setting announcement.
Last time Cynata went on a roll we had plenty of knockers come out of the woodwork claiming all sorts of negatives on the technology and the business plan and asking "why would such a technology be licensed to an australian company?" -- so well now ... tick, covered off refer to previous announcement.
No coincidence that additional trials including parkinsons is mentioned. Which company is planning on parkinsons trials ??? would they benefit from access to cynata's platform if it is safe and efficient method of delivering pharmaceutical quality cells ?? Is cynata on the brink of proving safety and efficacy?
Is there another partner out there that might give Fuji a run for its money?
DYOR
CYP Price at posting:
58.5¢ Sentiment: Buy Disclosure: Held
